Stockreport

OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development [Yahoo! Finance]

Ocugen, Inc.  (OCGN) 
PDF therapy for a single genetic defect, the platform is intended to work across many underlying mutations. The investment debate is whether that “gene-agnostic” concept can [Read more]